Theratechnologies Inc. expects to initiate a Phase III trial later this year for ThGRF, a candidate for HIV-associated lipodystrophy. At the same time, the Montreal-based company said it intends to restructure its senior management responsibilities and recruit a new chief executive officer. Luc Tanguay, the firm's current president and CEO, will assume the role of senior executive vice president and chief financial officer once a new CEO is named. (BioWorld Today)
Protein Design Labs Inc. and Abbott Laboratories entered a long-term agreement that gives Abbott broad access to PDL's technology for antibody humanization. (BioWorld Today)
Protein Design Labs Inc. and Abbott Laboratories entered a long-term agreement that gives Abbott broad access to PDL's technology for antibody humanization. (BioWorld Today)
BioMarin Pharmaceutical Inc. on Thursday released favorable data from a Phase III trial of Aryplase, an enzyme-replacement therapy for mucopolysaccharidosis-VI patients. (BioWorld Today)
BioMarin Pharmaceutical Inc. on Thursday released favorable data from a Phase III trial of Aryplase, an enzyme-replacement therapy for mucopolysaccharidosis-VI patients. (BioWorld Today)
